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TObjectives: The purpose of this study was to investigate whether a novel
fibroblast growth factor-2 gene formulation, providing a localized and sustained
availability of the adenoviral vector from a collagen-based matrix, in combina-
tion with CO2 transmyocardial laser revascularization would lead to an enhanced
angiogenic response and improved myocardial function.
Methods: Fibroblast growth factor-2 gene was delivered by means of an adenoviral
vector (adenoviral fibroblast growth factor-2) formulated in a collagen-based ma-
trix. The ischemic areas of 33 animals were then treated. Group 1 was treated with
CO2 transmyocardial laser revascularization; group 2 was treated with intramyo-
cardial injections of adenoviral fibroblast growth factor-2 in a collagen-based
matrix; group 3 had a combination treatment of matrix adenoviral fibroblast growth
factor-2 and CO2 transmyocardial laser revascularization; and group 4 received
injections with saline-formulated adenoviral fibroblast growth factor-2. Baseline left
ventricular function was assessed by echocardiography and cine magnetic resonance
imaging. Studies were repeated 6 weeks after treatment. Vascular development was
assessed using anti--actin immunohistochemistry.
Results: Matrix adenoviral fibroblast growth factor-2  transmyocardial laser
revascularization-treated areas had a 105% increase in arteriolar development
versus either treatment alone (P  .05) and a 390% increase compared with
saline-formulated adenoviral fibroblast growth factor-2 treatment alone (P 
.05). Contractility was significantly improved in matrix adenoviral fibroblast
growth factor-2  transmyocardial laser revascularization-treated areas as mea-
sured by myocardial wall thickening. This functional improvement was con-
firmed by cine magnetic resonance imaging, in which a 90% increase in the
contractility of the treated segments was demonstrated after matrix adenoviral
fibroblast growth factor-2  transmyocardial laser revascularation. The other
treatments provided significantly less restoration of myocardial function.
Conclusions: The increase in angiogenesis as a result of matrix adenoviral fibroblast
growth factor-2 gene therapy in combination with CO2 transmyocardial laser revascu-
larization is greater than that seen in either therapy alone. A concomitant improvement
in myocardial function was seen as a result of this angiogenic response.
The majority of patients who require intervention for their coronary arterydisease can be adequately treated by percutaneous coronary interventions orcoronary artery bypass grafting. However, a major reason for failure of these
treatments is their dependency on luminal size and coronary outflow. Methods to
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dent on vessel caliber therefore provide an important alter-
native treatment. Numerous experimental and clinical stud-
ies have evaluated gene therapy as a treatment for ischemic
heart disease.1-11 In addition, transmyocardial laser revas-
cularization (TMR) has been developed to treat end-stage
coronary artery disease.12-20 As with gene therapy, TMR’s
principal mechanism of action seems to be stimulation of
neovascularization.21-27 Additional laboratory work indi-
cates that combined therapy may be synergistic.28,29 We
have previously reported the successful use of a novel gene
delivery method,30,31 in which an adenoviral (Ad) vector is
formulated in a collagen-based matrix (termed a “gene-
activated matrix” [GAM]). The advantages of this approach
include improved vector retention at delivery sites and the
early deposition of a provisional matrix favorable for tissue
remodeling and neovascularization. We have also reported
the positive influence of CO2 TMR on treating ischemic
myocardium (including angiogenesis) and subsequent func-
tional outcome.25,26,32 This study determines whether the
combination of a GAM and CO2 TMR would lead to an
additive improvement in either neovascularization or left
ventricular function of chronically ischemic myocardium.
Materials and Methods
Animal Model
Animals received humane care as approved by the Center for
Experimental Animal Research at Northwestern University and in
compliance with the “Guide for the Care and Use of Laboratory
Animals” published by the National Institutes of Health (publica-
tion 85-23, revised 1985).
Operative Technique
In an effort to recreate the clinical situation, we used a standard
animal model of chronic myocardial ischemia.33,34 Thirty-six
Yorkshire pigs, weighing 12 to 15 kg, were anesthetized with
tiletamine hydrochloride (Telazol; 10 mg/kg), xylazine (0.25 mg/
kg), and atropine (2 mg) intramuscularly, followed by sodium
thiamylal (2.5%, 10 mg/kg) intravenously. After intubation, main-
tenance anesthesia was maintained with isoflurane (Abbott Labo-
ratories, Chicago, Ill). Before exposure of the heart, lidocaine (1
mg/kg) was administered intravenously. The same anesthetic reg-
imen was used for each for the 3 different surgical procedures that
were performed.
At the initial operation, with sterile technique, the heart was
exposed through a small left thoracotomy, and the pericardium was
opened. The proximal left circumflex artery was dissected free,
and an ameroid constrictor (Research Instruments Manufacturing,
Corvallis, Ore) with an internal diameter of 2.5 mm was placed in
the same location for each animal, specifically around the origin of
the left circumflex artery. The pericardium and chest were then
closed. The animals were allowed to recover and were ambulatory
before leaving the operating room suite. They were monitored
daily by a veterinarian and his staff as well as the surgical team.
Adequate food and water were provided, and intake and weights
were measured daily. Antibiotics were administered intramuscu-
1072 The Journal of Thoracic and Cardiovascular Surgery ● Malarly for 3 days postoperatively. Pain medications were also given
intramuscularly until the animals were ambulating without diffi-
culty and exhibiting normal activity levels.
Five weeks later, to evaluate the baseline regional contractility
and the precise areas of hypoperfusion versus infarction, contrast-
enhanced and cine magnetic resonance imaging (MRI) were per-
formed. While anesthetized, the animals were scanned on a 1.5-T
Siemens Symphony Scanner (Siemens Medical Systems, Erlan-
gen, Germany). Short-axis images every 10 mm were performed to
cover the entire left ventricular volume. Cine MRI provided eval-
uation of regional myocardial contractility, and contrast-enhanced
MRI provided information on the presence of any regional myo-
cardial injury. Animals received a routine clinically approved
contrast agent intravenously (Magnevist, Abbott Laboratories; 0.2
mmol · kg · wt; maximum rate of 10 mL/15 sec). At least 5 minutes
were allowed for the contrast to circulate, and then MRI was
performed at each of the cine short-axis locations.
After these studies, a second operation was performed through
a larger left thoracotomy in which the pericardium was reopened
and the heart was reexposed. Blood pressure and electrocardio-
graphic monitoring were used. Rest and dobutamine stress epicar-
dial echocardiography (7.5 MHz: model 128; Acuson Inc, Moun-
tain View, Calif) were performed to provide an assessment of the
viability of the myocardium and a method of determining the
extent of the ischemia. Dobutamine was administered intrave-
nously starting at 5 g · kg · min and titrated to a maximum
infusion rate of 50 g · kg · min to achieve a 100% increase in the
resting heart rate. There were no significant differences in resting
heart rates at operations 2 and 3 (96  18 vs 88  16, P  .8) or
between stress heart rates at operations 2 and 3 (194  27 vs 181
 21, P  .6). Similarly, mean arterial pressures demonstrated a
modest increase with stress but with no significant differences
between the resting and stress blood pressure measurements for
operations 2 and 3.
Two animals died after ameroid placement and before random-
ization. The remaining animals were then randomized into 1 of 4
groups at operation 2. Group 1: The ischemic area was treated with
CO2 TMR (20 channels, n  8). Group 2: The ischemic area was
treated with intramyocardial GAM (20 injections, n  8). The
GAM consisted of an adenovirus encoding the gene for human
fibroblast growth factor (FGF)2 (18 kD form) (AdFGF2) formu-
lated in a matrix of 1% bovine collagen and 1% bovine gelatin.32
A 27-gauge needle was used to deliver GAM into the ischemic
region as 20 injections of 100 L volume each (5  1010 viral
particles/injection) were placed as 1 injection per square centime-
ter of tissue. Group 3: A combination treatment of CO2 TMR and
GAM was administered; GAM was directly injected into TMR
channels (20 channels with 20 injections, 1 per channel, n  10).
Group 4: Treatment with identical intramyocardial injections with
saline-formulated AdFGF2 (20 injections, n  7) was adminis-
tered. The thoracotomies were then closed, and the animals were
allowed to recover. The aforementioned postoperative care was
then reinstituted. At the time of sacrifice (operation no. 3) 6 weeks
later, the animals underwent a repeat thoracotomy. At that time,
they underwent repeat rest and dobutamine stress echocardiogra-
phy and repeat contrast-enhanced and cine MRI. The animals were
then sacrificed, and the hearts were harvested for histologic anal-
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flex artery by the ameroid constrictor was performed.
Echocardiographic Analysis
The echocardiographic images were recorded on a half-inch vid-
eotape. End-diastolic and end-systolic images were then digitized
off-line from the videotape with a dedicated software package
(Prism Lite for Windows, Version 5.14; Tomtec Imaging Systems,
Broomfield, Colo). The digitized images were spatially calibrated,
and the endocardial and epicardial contours were traced. The
software then automatically calculated the wall motion along the
100 evenly distributed lines of site around the contour. By standard
segmental contraction analysis, the mean wall motion score for
each segment was obtained (48 segments for each short-axis
image). Segmental contraction was defined as the change in wall
thickness between systole and diastole as measured in centimeters.
Echocardiographic analysis was performed by an independent
observer blinded to the treatment that the animals received. Seg-
mental contraction was compared in all segments at all times using
each animal as its own control. As an additional control, the
historical data from untreated animals were compared with those
of the gene therapy-treated animals.
Magnetic Resonance Imaging Analysis
Regional contractility, as measured by wall thickening, was deter-
mined with commercial software (ARGUS, Siemens Medical Sys-
tems) in 72 segments for each animal by the modified centerline
method. The measurements were performed from short-axis im-
ages at the midpapillary region of the left ventricle, as well as 1
image above (10 mm) and 1 image below (10 mm) this region.
With contrast enhancement, areas with an infarction appear to be
hyperenhanced. Assessment of the degree of hyperenhancement
when present was performed by outlining only the hyperenhanced
region of each segment. The percent infarction was then calculated
on the basis of the outlined area of hyperenhancement compared
with the total area of each segment.
Histologic Analysis
Tissue samples were fixed with 4% paraformaldehyde in Sören-
son’s phosphate and processed as paraffin-embedded sections. For
routine histochemistry, sections were stained with hematoxylin-
eosin and Mallory’s trichrome. Immunohistochemistry was also
performed to detect -actin expression by smooth muscle cells. In
brief, anti--actin clone 1A4 (Dako, Carpinteria, Calif) was used
as a primary antibody, horseradish peroxidase-conjugated anti-
mouse immunoglobulin G as a secondary antibody (Vector Lab-
oratories, Burlingame, Calif), and 3,3=-diaminobenzidine (DAB)
as a detection agent.
The techniques used for morphometric analyses have been
described and entail measurements throughout the entire left ven-
tricle.26,27 This method, in which muscular wall areas are mea-
sured, was selected over direct measurement of vessel size as being
more accurate (measurement of vessel size requires perfusion
fixation at the proper pressure to prevent vessel distortion or
collapse). 30,31 Immunostained paraffin sections taken from non-
ischemic and ischemic areas of the heart (n  4 per animal) were
first photographed by a blinded observer as nonoverlapping mi-
croscopic fields (40 total magnification), so the entire section
The Journal of Thoracicwas captured. An image analysis software package (Image-Pro
Plus, Media Cybernetics, Silver Spring, Md) was then used to
score individual pixels in these images as DAB positive or nega-
tive, based on a mask set to recognize all DAB positive cells but
corrected for the background staining (ie, myocardium free of
visible muscular arterioles). The program then converted pixel
measurements into an area measurement, and the highest 6 data
values for each section (representing the areas densest in arte-
rioles) were grouped. These data are presented as the total arteriole
wall area (in cubic millimeters) per microscopic field.
Statistical Analysis
All results are presented as mean  SD. One-way analysis of
variance was used to compare differences in arteriogenesis and
contractility between the 4 groups. Paired t tests were performed
when appropriate for comparison with baseline data. Bonferroni
correction was used for multiple comparisons. All statistical tests
were 2-tailed.
Results
In addition to the aforementioned animals that died before
randomization, 1 animal was noted to have significant myo-
cardial infarction just before randomization, based on hy-
perenhancement seen on MRI. This animal was therefore
excluded. There were no significant resting hemodynamic
or electrocardiographic differences between the animals at
the second and third operations. In addition, all animals
underwent the same degree of dobutamine stress at each
operation.
Myocardial function, as assessed by echocardiographic
measurements of the segmental contraction (Figure 1), re-
vealed hypokinesis of the ischemic zone after placement of
the ameroid constrictor; there was no change, however, in
the segmental contractions in the nonischemic zone (data
not shown). There were also no significant differences in the
baseline resting function between groups, and these mea-
surements were consistent with previous controls.32 The
posttreatment resting function of the ischemic zone, how-
ever, showed a significant improvement for all groups, with
the greatest improvements being seen in the TMR- and/or
GAM-treated groups (73%-101% improvement). Animals
treated with saline-formulated AdFGF2 by comparison had
relatively modest improvements (24%).
Further confirmation of this posttreatment functional im-
provement was obtained by cine MRI (Figure 2). Although
function was improved for all treatment groups, the most
significant improvement was seen in the animals treated
with the combination of the GAM and CO2 TMR. Of the
216 segments in the treated area, 112 segments (52%)
demonstrated improvement in contractility after CO2 TMR
alone; 110 segments (51%) showed improvement after
GAM alone, and 192 segments (89%) demonstrated im-
proved contractility after treatment with the combination of
GAM CO2 TMR (P .001, GAM CO2 TMR vs GAM
or CO2 TMR alone). In contrast, only 13 of the segments
and Cardiovascular Surgery ● Volume 129, Number 5 1073
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ETFigure 1. Contractility as assessed by echocardiography. Resting echo shows the increase of wall thickening
in the ischemic zone after treatment. The percentages in the posttreatment bars are improvement compared
with pretreatment. The matrix adenoviral fibroblast growth factor (AdFGF2)  CO2 transmyocardial laser
revascularization (TMR)-treated group had the most significant improvement compared with the other
groups.Figure 2. Contractility as assessed by cine magnetic resonance imaging (MRI). The percentage of improved
cine MRI segments were calculated. The matrix AdFGF2  CO2 TMR-treated group demonstrated the most
significant improvement compared with the other groups. (*P < .05 aqueous AdFGF2 versus all other
groups.)
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formulated AdFGF2. On the basis of previous work using
this same animal model and cine MRI analysis, only 12 of
the 216 segments (6%) in an untreated controlled group
typically show any improvement in function.11 The non-
ischemic segments for each group showed no change in
function. Contrast-enhanced MRI results revealed no evi-
dence of myocardial infarction for any segments.
Histologic assessment confirmed no evidence of signif-
icant infarctions as noted on hematoxylin-eosin or Mal-
lory’s trichrome staining. Although neovascularization was
noted at treatment sites in all groups, vessel density and
maturity were much more pronounced in the TMR- and/or
GAM-treated groups compared with the saline-formulated
AdFGF2 group (Figure 3). In particular, GAM-treated sites
(with or without concomitant TMR) revealed a high density
of muscular walled arterioles (as demonstrated by anti--
actin staining). The arteriolar wall area of the ischemic zone
was compared in a ratio with the arteriolar area of the
nonischemic zone for each treatment group. This measure of
arteriogenesis was greatest for the animals treated with
GAM  CO2 TMR. Because of the range of the results
yielding broad standard deviations, there were no significant
differences between the CO2 TMR combination treatment
and animals treated with either GAM or CO2 TMR alone.
There was, however, a statistically significant difference
Figure 3. Arteriolar development. The degree of angio
ischemic and nonischemic zones of each animal. As s
increase in arteriole area versus either treatment alo
AdFGF2 treatment. (*P value vs aqueous AdFGF2.)between those treatments and the group that was treated
The Journal of Thoracicwith the saline-formulated form of the AdFGF2. As ex-
pected, there was no difference in the nonischemic area
between these 2 groups (5%).
Representative sections from the ischemic zone of each
group are presented in Figure 4. A robust neovascularization
response, marked by numerous muscular arterioles, was
seen in animals treated with CO2 TMR, matrix-formulated
AdFGF2, and the combination of both. The most striking
feature of this response was both a greater number and a
greater size of these vessels of muscular-walled vessels than
that observed in saline-formulated AdFGF2.
Discussion
The natural response to myocardial ischemia resulting from
coronary artery disease is neovascularization. This angio-
genic process is a physiologic attempt to limit myocardial
ischemia; however, despite this goal it may fail to provide
adequate perfusion and restoration of function to the isch-
emic myocardium. In an attempt to improve on this process,
mechanical and pharmacologic stimulation of additional
angiogenesis have been tried. Such means of increasing
angiogenesis include TMR and the delivery of angiogenic
growth factors (as either recombinant proteins or gene-
encoding vectors). We previously demonstrated that both
these modalities can stimulate angiogenesis, increase per-
fusion, and restore myocardial function. Despite favorably
sis is quantified by the arteriole area ratio between
, matrix AdFGF2  CO2 TMR-treated areas had a 27%
d a 470% increase compared with saline-formulatedgene
hown
ne anpreclinical results with angiogenic growth factors such as
and Cardiovascular Surgery ● Volume 129, Number 5 1075
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ever, clinical responses are limited.9 The key limitation of
growth factor protein therapy seems to be difficulty in
achieving sustained therapeutic protein concentrations at the
intended sites.
On the basis of this past experience, we reasoned that a
combined application of CO2 TMR plus angiogenic gene
delivery might induce an additive level of neovasculariza-
tion adequate for achieving the ultimate goal of such ther-
apies, namely, improved left ventricular functioning. For
these therapies to achieve the maximal possible additive
benefit, we also reasoned that gene vectors should be de-
livered directly into TMR channels, rather than at adjacent
sites. The traditional gene therapy approach of delivering
aqueous-formulated gene vectors, however, is unlikely to
yield meaningful retention within TMR channels. Matrix-
immobilized vectors, or GAMs, on the other hand, are
ideally suited for both direct application to and retention at
wound sites,30,31 and therefore we devised a treatment strat-
egy in which laser TMR would first be applied to the
ischemic myocardial territory, followed immediately by di-
rect injection of GAM into the TMR channels. For a GAM,
we selected an adenovirus encoding FGF2 formulated in a
collagen/gelatin admixture, based on its previous successful
use to induce arteriogenesis in skeletal muscle wounds.30
Induction of higher caliber vessels, such as muscular arte-
rioles, is likely the best pattern of neovascularization for
ischemic tissues, in that arterioles allow for greater blood
inflow compared with microvasculature and muscular-
walled vessels provide the potential for vasoregulation.
In agreement with our previous studies,11,30 collagen-
immobilized AdFGF2 induced a significantly greater arte-
riogenic response in treated tissue compared with saline-
formulated vector. In the earlier studies, we were able to
attribute this difference to a greater retention of AdFGF2 at
delivery sites by the matrix formulation. We suggest that a
Figure 4. Neovascularization after gene therapy and TM
the ischemic zones after treatment. Notice the enha
muscular arterioles, in CO2 TMR/AdFGF2 in gene-ac
formulated AdFGF2 group.similar situation also occurred in the present work, and
1076 The Journal of Thoracic and Cardiovascular Surgery ● Mafurthermore that the data presented now demonstrate the
value of enhanced arteriogenesis, namely, an improvement
in myocardial functional recovery as assessed by both echo-
cardiography and cine MRI.
Not surprisingly, on the basis of previous studies, we
observed an enhanced arteriogenic response and restoration
of myocardial function with the combination of CO2 TMR
and GAM AdFGF2. This reached significance for the cho-
sen end points, including functional improvement as as-
sessed by echocardiography and MRI, as well as histologic
analysis of arteriolar development. The establishment of
this significant arteriogenesis is critical because its induc-
tion provides the significant perfusion to reverse myocardial
ischemia. In addition, the histologic analysis confirms that
the matrix-formulated vectors are present in the TMR chan-
nels posttreatment. Furthermore, this arteriogenesis is en-
hanced in the TMR-treated areas, more significantly than
TMR or GAM treatment alone.
Contrast-enhanced MRI results also demonstrated no
evidence of myocardial infarction for any of the segments.
This was also confirmed by histologic assessment.
These results indicate that the combination of GAM
AdFGF2 plus CO2 TMR provides a salutary angiogenic
response that has significant clinical implications and in
planned translational work may provide a better treatment in
combination than either therapy alone.
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